Tavernor S J, Wong I C, Newton R, Brown S W
David Lewis Centre, Warford, Nr Alderley Edge, Cheshire, UK.
Seizure. 1995 Mar;4(1):67-71. doi: 10.1016/s1059-1311(05)80082-2.
Eight patients rechallenged with lamotrigine after initial exposure which resulted in a skin rash are reported. On reintroduction of the lamotrigine, six of the patients had no recurrence of the rash. Of the other two patients, one had the occurrence of a mild fluctuating and qualitatively different skin rash on rechallenge. The other patient had developed a dose-related rash on initial challenge resulting in a dose reduction. The first attempt to re-increase the dose resulted in reappearance of the rash which again disappeared on dose reduction. However a further attempt to re-increase the dose did not result in reappearance of a rash. It is suggested that patients who experience a rash but good therapeutic response to lamotrigine might be considered for re-dosing.
报告了8例在初次接触拉莫三嗪后出现皮疹,之后再次接受该药激发试验的患者。再次引入拉莫三嗪时,6例患者皮疹未复发。另外2例患者中,1例在再次激发试验时出现轻度波动且性质不同的皮疹。另1例患者在初次激发试验时出现了与剂量相关的皮疹,导致剂量减少。首次尝试增加剂量导致皮疹再次出现,再次减少剂量后皮疹又消失。然而,进一步尝试增加剂量并未导致皮疹再次出现。建议对于出现皮疹但对拉莫三嗪有良好治疗反应的患者,可以考虑重新给药。